Mumbai, India & Naples, Florida | April 10, 2026
Lupin Limited has announced the U.S. launch of Dapagliflozin Tablets (5 mg and 10 mg) following approval of its Abbreviated New Drug Application (ANDA) by the U.S. Food and Drug Administration (FDA). The product is bioequivalent to Farxiga®, a widely used SGLT2 inhibitor indicated for type 2 diabetes and related conditions, marking a significant step in expanding access to cost-effective generic therapies in the United States. This launch reinforces Lupin’s commitment to strengthening its presence in the U.S. pharmaceutical market while supporting affordable treatment options for chronic diseases with high global prevalence.
FDA Approval Strengthens Generic Drug Access in the U.S.
The approval of Lupin’s ANDA confirms that its Dapagliflozin tablets meet stringent FDA requirements for quality, safety, and bioequivalence, ensuring therapeutic equivalence to the reference listed drug, Farxiga®. As a sodium-glucose co-transporter 2 (SGLT2) inhibitor, dapagliflozin plays a critical role in glycemic control by promoting glucose excretion through urine, thereby helping manage blood sugar levels in patients with type 2 diabetes.
The availability of a generic version is expected to reduce treatment costs and improve patient access, particularly in the U.S., where diabetes remains a major public health challenge. This development highlights the importance of regulatory pathways such as ANDA approvals in accelerating access to essential medicines while maintaining compliance with Good Manufacturing Practices (GMP) and quality standards.
Expanding Lupin’s Global Pharmaceutical Footprint
Advertisement
Lupin’s launch of dapagliflozin in the U.S. further strengthens its global pharmaceutical portfolio, which spans over 100 markets and includes branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients (APIs). The company’s strong presence in key therapeutic areas such as cardiovascular, anti-diabetic, respiratory, and central nervous system disorders positions it as a leading player in addressing chronic disease burdens worldwide. With 15 manufacturing facilities and 7 research centers globally, Lupin continues to invest in innovation, regulatory compliance, and supply chain excellence to ensure the consistent delivery of high-quality medicines. This launch also reflects the company’s strategic focus on expanding its U.S. generics business, one of the most competitive and regulated pharmaceutical markets globally.
Regulatory Compliance and Quality Assurance in Generic Drug Development
From a cGxP perspective, the successful approval and launch of dapagliflozin tablets demonstrate Lupin’s adherence to strict regulatory frameworks, including GMP, Good Laboratory Practices (GLP), and Good Distribution Practices (GDP). The ANDA process requires comprehensive data on bioequivalence, manufacturing processes, and quality control systems, ensuring that the generic product delivers the same therapeutic outcomes as the innovator drug.
Lupin’s ability to meet these requirements underscores its expertise in regulatory submissions and quality assurance, which are critical for maintaining trust among healthcare providers and patients. Furthermore, the launch supports broader healthcare goals by enabling sustainable and scalable access to essential medicines, particularly in the management of chronic diseases such as diabetes.
The launch of Dapagliflozin Tablets by Lupin in the United States represents a significant advancement in generic drug accessibility and regulatory-driven pharmaceutical innovation. By providing a cost-effective alternative to Farxiga®, Lupin contributes to improving patient outcomes and expanding treatment options in diabetes care. This milestone highlights the critical role of ANDA approvals, quality compliance, and global manufacturing capabilities in delivering safe and effective medicines to patients worldwide. As the demand for affordable healthcare solutions continues to grow, initiatives like this underscore the importance of generic pharmaceuticals in enhancing healthcare accessibility and sustainability.
Source: Lupin press release
